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Abstract
Background The aim of this study was to compare the
intraosseous concentrations and the inhibitory effects on
the growth of Staphylococcus aureus of 1 g versus 2 g of
intravenous (IV) prophylactic cefazolin in total knee
arthroplasty (TKA).
Materials and methods Eighteen patients (21 knees) with
primary knee osteoarthritis were divided into two groups
receiving 1 g (12 patients: 14 knees) versus 2 g (six
patients: seven knees) IV prophylactic cefazolin prior to
the incision in TKA. Subchondral bone samples (proximal
tibia, distal femur) were taken during the operation. These
samples were analyzed for intraosseous concentration of
cefazolin and their inhibitory effects on the growth of S.
aureus, using high-performance liquid chromatography
(HPLC) and agar disc diffusion bioassays.
Results The mean intraosseous concentration in the 2 g
dose group was significantly higher than in the 1 g dose
group in the proximal tibia (p = 0.007) and distal femur
(p = 0.016). There were no significant differences between
the two groups in terms of mean inhibitory effects in the
proximal tibia or distal femur (p[ 0.05). No significant
correlations were found between the intraosseous concen-
trations and inhibitory effects in the proximal tibia
(r = 0.18, p = 0.52) and distal femur (r = -0.29,
p = 0.30).
Conclusion IV cefazolin at a dose of 2 g produced
greater intraosseous concentrations overall than a dose of
1 g. However, the higher intraosseous concentrations did
not correlate with higher inhibitory effects.
Level of evidence Level III.
Keywords Cefazolin  Knee arthroplasty  Prophylaxis 
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Introduction
Prophylactic antibiotics are known to reduce the risk of
perioperative and/or postoperative infection [1–3]. How-
ever, some previous studies had reported that systemic
antibiotics may not prevent all postoperative infections [4–
6]. Moreover, conventional systemic dosages may not
provide adequate tissue concentrations against more resis-
tant organisms, such as coagulase-negative staphylococci
[7]. The current literature recommends the intravenous (IV)
administration of cefazolin, 1–2 g [1], within 1 h prior to
making the incision. This antibiotic may be repeated every
2–5 h during the operation and should be stopped within
24 h following the operation [8, 9]. However, little is
known about the differences in the intraosseous concen-
trations of cefazolin or the inhibitory effects on the growth
of Staphylococcus aureus between an IV dose of 1 g and a
dose of 2 g.
This study aims to compare the intraosseous concen-
trations and the inhibitory effects on the growth of S.
aureus of IV prophylactic cefazolin at dosages of 1 versus
2 g in total knee arthroplasty. At this point, we hypothesize
that the intraosseous concentrations and the inhibitory
& Chayanin Angthong
chatthara@yahoo.com
1 Department of Orthopaedics, Faculty of Medicine,
Thammasat University, Pathum Thani 12120, Thailand
2 Department of Chemistry, Faculty of Science and
Technology, Thammasat University, Pathum Thani, Thailand
3 The Surgical Unit, Thammasat University Hospital,
Pathum Thani, Thailand
123
J Orthopaed Traumatol (2015) 16:331–334
DOI 10.1007/s10195-015-0370-y
effects in the group given cefazolin at a dose of 2 g are
possibly higher than those in the group given a dose of 1 g.
Materials and methods
During the period between May, 2011 and February, 2013,
patients with primary knee osteoarthritis were recruited to
participate in this study. The inclusion criteria were patients
with primary knee osteoarthritis while the exclusion criteria
included patients with post-traumatic or post-infectious
knee conditions, allergies to cephalosporin or penicillin,
serum creatinine levels [1.5 mg%, creatinine clearance
\55 ml/min, probenecid intake, post-steroid treatment,
chemotherapy, those who were post-knee arthroplasty or
high tibial osteotomy, immunocompromised hosts, and
those with deleterious medical conditions. Eighteen patients
were recruited into our study using the inclusion and
exclusion criteria. The 18 patients (21 knees) were divided
into two groups in accordance with their IV prophylactic
cefazolin dosages (cefazolin M. H., M & H Manufacturing
Co., Ltd., Thailand) of 1 g (12 patients: 14 knees, which
were operated by B.P. and P.P.) versus 2 g (six patients:
seven knees, which were operated by N.T.) administered
before the incision was made in their total knee arthroplasty.
All patients’ baseline data were prospectively collected,
including the intraosseous concentrations of cefazolin and
the inhibitory effects on the growth of S. aureus, which
were prospectively collected from further analyses. The
group with the IV cefazolin dose of 1 g consisted of nine
females and three males with a mean age of
70.1 ± 4.6 years (61–79 years of age). During the same
period we retained a group with an IV cefazolin dose of 2 g.
This group consisted of five females and one male with a
mean age of 68.4 ± 3.0 years (64–73 years of age). There
were no significant differences in the mean age and genders
between the two groups (p = 0.40 for age, p = 1.00 for
gender). The mean weights of the patients were
61.2 ± 8.4 kg for the group with a 1 g dose and
62.0 ± 8.2 kg for the group with a dose of 2 g (p = 0.84).
All patients were prepared for the TKA operation with
standard, sterile technique. They were administered IV
cefazolin, at a dose of 1 or 2 g, prior to tourniquet inflation
and before the incision had been made. After performing
knee arthrotomy and bone cutting at the distal femur and at
the proximal tibia, our experienced knee surgeons, B.P.,
P.P., and N.T. (with the same level of experience), pro-
vided bone from the segments that had been removed from
each patient to a researcher (P.K.) who extracted only
subchondral bone at a size of 2.5 9 2.5 mm for further
analyses while under sterile technique. The period of time
between IV cefazolin injection and sample collection was
recorded.
Each sample was processed by the antibiotic broth
elution assay [10]. The solution from a previous process
was further analyzed for concentration using high-perfor-
mance liquid chromatography–photodiode array detection
[HPLC–DAD; Shimadzu (Nexara LC-30A)]. The unit of
this intraosseous concentration was ‘lg/g’, which was
derived from the comparison of a 1 g sample of the sub-
chondral bone. A validation study was done of the
extraction and HPLC–DAD technique using bone samples
analyzed with known concentrations of cefazolin. All
samples were analyzed by a specialist (W.T.) who was
blinded to the IV cefazolin dose in each sample.
The bioactivity of each sample was determined using an
agar disc diffusion bioassay with S. aureus (ATCC 25923)
[10]. The antibiotic bioassay was to determine the inhibi-
tory effect of intraosseous cefazolin, which was compared
with the standard minimal inhibitory concentration (MIC)
of serum cefazolin (30 lg/ml). The technique was based on
the inhibitory activity of discs (Oxoid, UK) containing a
standard concentration of cefazolin. Standard paper discs
and samples were placed on S. aureus-seeded agar (Muller
Hinton Agar, BD, USA) and incubated for 18 h at 37 C.
All samples were analyzed by our researcher (N.M.) who
was blinded to the IV cefazolin dose in each sample. The
standard MIC of serum cefazolin would inhibit the growth
of S. aureus at least 18 mm from the center of the sample.
All samples were analyzed by a staff person in the labo-
ratory who was also blinded to the IV cefazolin dose used
in each sample.
Statistical analyses
Statistical analysis was performed using the SPSS software
version 13.0 (SPSS Inc., Chicago, IL, USA). ANOVA was
used to analyze the statistical significance of the differ-
ences in the values of the intraosseous concentration of
cefazolin (lg/g) and the inhibitory effect on S. aureus
growth on the agar disc (mm) between the two different
groups of IV cefazolin doses (1 versus 2 g). The correla-
tions between the intraosseous concentrations of cefazolin
(lg/g) and the inhibitory effects of S. aureus growth on
agar disc (mm) were analyzed and interpreted via Pear-
son’s correlation coefficient (r). Categorical variables were
analyzed using the Chi-squared test. The level of signifi-
cance was set at p\ 0.05.
Results
The mean times between cefazolin injection and sample
collection were 50.1 ± 6.5 min for femur and
53.1 ± 6.5 min for tibia in the group with IV cefazolin 1 g,
compared with 58.9 ± 23.1 min for femur and
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67.9 ± 23.1 min for tibia in the group with IV cefazolin
2 g. There were no significant differences in these mean
times for the same corresponding areas of sample collec-
tion between the two groups (femur, p = 0.32; tibia,
p = 0.11).
Total mean intraosseous concentrations of cefazolin
were 26.6 ± 11.7 lg/g in the proximal tibia and
30.5 ± 19.5 lg/g for the distal femur. The mean intraoss-
eous concentrations of the group receiving cefazolin 2 g
were significantly higher than the group receiving cefazolin
1 g in the proximal tibia (p = 0.007) and distal femur
(p = 0.016) (Table 1).
From Pearson’s correlation analyses, there were no
significant correlations between the levels of intraosseous
concentration and inhibitory effects seen in the proximal
tibia (r = 0.18, p = 0.52) and distal femur (r = -0.29,
p = 0.30).
The total mean inhibitory effects of cefazolin were
10.0 ± 5.4 mm for the proximal tibia and 11.6 ± 5.4 mm
for the distal femur. The mean inhibitory effects in the two
groups (cefazolin 1 g versus 2 g at both proximal tibia and
distal femur) were less than 34.6 ± 0.5 mm, which was
shown to be the mean inhibitory effect of the standard MIC
of serum cefazolin (30 lg/ml) in this present study
(Table 2). There were no significant differences between
the two groups in terms of the mean inhibitory effects at the
proximal tibia or distal femur via the analyses on agar disc
diffusion bioassay (proximal tibia, p = 0.33; distal femur,
p = 0.63).
Discussion
Although current literature recommends administration of
a dosage of intravenous (IV) cefazolin of 1–2 g [1] as the
dose for prophylaxis in TKA, there is, as far as we know, a
lack of basic research that has shown the actual intraoss-
eous concentrations and inhibitory effects of cefazolin at
those recommended doses. Our study is possibly one of the
earliest reports on the importance of these aspects. Based
on the present study, we found that the mean intraosseous
concentrations in the group receiving 2 g of cefazolin were
significantly higher than in the group receiving 1 g, at the
proximal tibia (p = 0.007) and distal femur (p = 0.016).
However, the mean intraosseous concentrations of the 1 g
group (22.6 lg/g) and the 2 g group (44.1 lg/g) at the
distal femurs were higher than the concentrations seen in a
previous study (9.2 lg/g) [7].
On the other hand, there were no significant differences
between the two groups in terms of the mean inhibitory
effects at either the proximal tibia or distal femur via agar
disc diffusion bioassay (proximal tibia, p = 0.33; distal
femur, p = 0.63). Although a previous report had shown
that high-dose cefazolin could be used for prophylaxis in
an animal study [11], surgeons should keep in mind that,
based on our findings, when they consider IV cefazolin at
a dose of 2 g for preoperative prophylaxis, it should be
used with care. This is especially true for patients with
reduced renal function. In addition to the results that
showed no significant differences between the two groups
in terms of mean inhibitory effects, we found that the
mean inhibitory effects in the two groups (cefazolin dose
of 1 versus 2 g at both the proximal tibia and distal femur)
were less than the mean inhibitory effect of the standard
MIC of serum cefazolin at 30 lg/ml. Pearson’s correla-
tion analyses showed that there were no significant cor-
relations between the intraosseous concentrations and the
inhibitory effects in either the proximal tibia (r = 0.18,
p = 0.52) or distal femur (r = -0.29, p = 0.30). Higher
cefazolin dosages would not provide higher inhibitory
effects. At this point, we hypothesize that the standard
MIC of intraosseous cefazolin may not be directly related
to the inhibitory effects, which are different from the
relationship between the standard MIC of serum cefazolin
and its inhibitory effects via the agar disc diffusion
bioassay. In addition, the intraosseous area may contain a
threshold inhibitory effect of cefazolin that gives no
greater inhibitory effect from a higher dose of cefazolin.
Further studies are needed to test the inhibitory effects of
intraosseous cefazolin directly with the standard MIC of
Table 1 Intraosseous
concentrations of cefazolin in
the two groups
Parameters IV cefazolin 1 g IV cefazolin 2 g P value
Cefazolin concentration at proximal tibia (lg/g) 21.4 ± 11.4 35.5 ± 5.1 0.007*
Cefazolin concentration at distal femur (lg/g) 22.6 ± 8.7 44.1 ± 25.8 0.016*
* Significant difference
Table 2 Mean inhibitory
effects in the two groups
Parameters IV cefazolin 1 g IV cefazolin 2 g P value
Mean inhibitory effect at proximal tibia (mm) 11.1 ± 6.1 8.4 ± 4.2 0.33
Mean inhibitory effect at distal femur (mm) 12.2 ± 6.1 10.9 ± 4.6 0.63
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intraosseous cefazolin rather than relative tests with the
standard MIC of serum cefazolin.
There were some limitations in the present study. First
of all, bone resection at the distal femur and at the proximal
tibia for the analyses of intraosseous concentrations and
inhibitory effects of cefazolin were performed only once
after knee arthrotomy. There was no subsequent bone
sampling for further analyses of the same parameters at the
end of the operation. Therefore, the change in intraosseous
concentration of cefazolin over the operating time could
not be determined at this point. A possible decrease in
concentration at the end of wound closure, including the
periods when suturing and insertion of drains may be a
source of contamination, was not clarified in the study. The
protective effect of the higher dose (2 g) of cefazolin may
be more beneficial than that of the lower dose (1 g) due to
the longer persistence of the inhibitory effect, particularly
in the final period of the operation. A previous study found
that biofilm formation could develop for up to 1–2 days
[12]; therefore, hypothetically, the higher dose (2 g) of
cefazolin might be more beneficial than the lower dose of
1 g. Second, the recommendations for surgeons from the
results of the present study might appear to be weak
because of the lack of evidence concerning relationships
between the intraosseous concentration of cefazolin, its
inhibitory effect and the related infection. This issue relates
to the previous limitation mentioned, as there was no
clarification of those relationships during the final period of
the operation. Future study may help to clarify these issues.
IV cefazolin at a dose of 2 g provides greater intraoss-
eous concentrations in both the proximal tibia and distal
femur than does a dose of 1 g. However, its higher
intraosseous concentration does not correlate with higher
inhibitory effects. Surgeons have to weigh the advantages
and disadvantages when considering IV cefazolin at a dose
of 2 g for preoperative prophylaxis in total knee
arthroplasty.
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